[HTML][HTML] Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and …
HL Kindler, D Niedzwiecki, D Hollis… - Journal of Clinical …, 2010 - ncbi.nlm.nih.gov
HL Kindler, D Niedzwiecki, D Hollis, S Sutherland, D Schrag, H Hurwitz, F Innocenti…
Journal of Clinical Oncology, 2010•ncbi.nlm.nih.govPurpose The combination of gemcitabine plus bevacizumab produced a 21% response rate
and a median survival of 8.8 months in a multicenter phase II trial in patients with metastatic
pancreatic cancer. These encouraging data led Cancer and Leukemia Group B (CALGB) to
conduct a double-blind, placebo-controlled, randomized phase III trial of gemcitabine/
bevacizumab versus gemcitabine/placebo in advanced pancreatic cancer patients.
and a median survival of 8.8 months in a multicenter phase II trial in patients with metastatic
pancreatic cancer. These encouraging data led Cancer and Leukemia Group B (CALGB) to
conduct a double-blind, placebo-controlled, randomized phase III trial of gemcitabine/
bevacizumab versus gemcitabine/placebo in advanced pancreatic cancer patients.
Abstract
Purpose
The combination of gemcitabine plus bevacizumab produced a 21% response rate and a median survival of 8.8 months in a multicenter phase II trial in patients with metastatic pancreatic cancer. These encouraging data led Cancer and Leukemia Group B (CALGB) to conduct a double-blind, placebo-controlled, randomized phase III trial of gemcitabine/bevacizumab versus gemcitabine/placebo in advanced pancreatic cancer patients.
ncbi.nlm.nih.gov
